Cart
sales@molnova.com
Piritrexim
CAS No. 72732-56-0
Piritrexim( —— )
Catalog No. M34017 CAS No. 72732-56-0
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 532 | Get Quote |
|
| 5MG | 922 | Get Quote |
|
| 25MG | 1463 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePiritrexim
-
NoteResearch use only, not for human use.
-
Brief DescriptionPiritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
-
DescriptionPiritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetDHFR
-
RecptorDHFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number72732-56-0
-
Formula Weight325.37
-
Molecular FormulaC17H19N5O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC=1C2=C(N=CC1CC3=C(OC)C=CC(OC)=C3)N=C(N)N=C2N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Fanotaprim
Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor. Fanotaprim inhibits the growth of T. gondii strains with a TgDHFR IC50 of 1.57 ± 0.11 nM and a hDHFR IC50 of 308?±?71 nM and a hDHFR to TgDHFR selectivity ratio of 196.
-
P 218
P 218 is a novel DHFR inhibitor with antimalarial activity and antifolate effects and can be used to study Buruli ulcer.
-
DS44960156
DS44960156 is a novel selective inhibitor of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) that inhibits both MTHFD2 and MTHFD1 and can be used in cancer research.
